NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

$14.80 -0.45 (-2.95 %)

(As of 04/19/2018 11:49 AM ET)

Previous Close$15.25

Today's Range$14.70 - $15.27

52-Week Range$11.90 - $20.40

Volume121,630 shs

Average Volume713,005 shs

Market Capitalization$769.18 million

P/E Ratio-43.57

Dividend YieldN/A

Beta1.12

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:VNDA

CUSIP92165910

Webwww.vandapharmaceuticals.com

Phone202-734-3400

Debt

Debt-to-Equity RatioN/A

Current Ratio2.41%

Quick Ratio2.40%

Price-To-Earnings

Trailing P/E Ratio-43.57

Forward P/E Ratio-164.44

P/E GrowthN/A

Sales & Book Value

Annual Sales$165.08 million

Price / Sales4.52

Cash FlowN/A

Price / CashN/A

Book Value$2.92 per share

Price / Book5.07

Profitability

EPS (Most Recent Fiscal Year)($0.35)

Net Income$-15,560,000.00

Net Margins-9.43%

Return on Equity-11.94%

Return on Assets-7.53%

Miscellaneous

Employees273

Outstanding Shares50,440,000

How to Become a New Pot Stock Millionaire

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.08. The biopharmaceutical company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. The firm's quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.08 earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Vanda Pharmaceuticals.

What price target have analysts set for VNDA?

5 Wall Street analysts have issued 1-year price targets for Vanda Pharmaceuticals' stock. Their predictions range from $18.00 to $27.00. On average, they expect Vanda Pharmaceuticals' share price to reach $22.40 in the next year. View Analyst Ratings for Vanda Pharmaceuticals.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 2,380,973 shares, a drop of 29.3% from the March 15th total of 3,367,547 shares. Based on an average daily volume of 1,242,810 shares, the days-to-cover ratio is currently 1.9 days. Approximately 4.9% of the company's stock are sold short.

Who are some of Vanda Pharmaceuticals' key competitors?

Some companies that are related to Vanda Pharmaceuticals include Prothena (PRTA), Impax Laboratories (IPXL), Zogenix (ZGNX), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Endo International (ENDP), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD), PTC Therapeutics (PTCT), Revance Therapeutics (RVNC), Mallinckrodt (MNK), WAVE Life Sciences (WVE) and Epizyme (EPZM).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:

H. Thomas Watkins, Independent Chairman of the Board (Age 64)
Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director (Age 57)
James Patrick Kelly, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
Gian Piero Reverberi, Senior Vice President, Chief Compliance Officer (Age 51)
Richard L. Gulino, Senior Vice President, General Counsel, Secretary (Age 54)
Gunther Birznieks, Senior Vice President - Business Development (Age 48)
Kenneth M. Bate, Independent Director (Age 66)
Michael F. Cola, Independent Director (Age 57)
Richard W. Dugan, Independent Director (Age 75)
Vincent J. Milano, Independent Director (Age 53)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Media headlines about VNDA stock have trended somewhat negative on Thursday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of -0.03 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $14.80.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $769.18 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]

MarketBeat Community Rating for Vanda Pharmaceuticals (VNDA)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		307 (Vote Outperform)
Underperform Votes:		138 (Vote Underperform)
Total Votes:		445

MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Vanda Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.40, suggesting that the stock has a possible upside of 51.35%. The high price target for VNDA is $27.00 and the low price target for VNDA is $18.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$22.40	$22.1667	$21.8333	$21.8333
Price Target Upside:	51.35% upside	15.45% upside	53.22% upside	36.46% upside

Vanda Pharmaceuticals (NASDAQ:VNDA) Consensus Price Target History

Price Target History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/22/2018	Oppenheimer	Reiterated Rating	Buy		Low
2/28/2018	Seaport Global Securities	Reiterated Rating	Buy	$21.00	Low
2/13/2018	Jefferies Group	Reiterated Rating	Buy	$20.00	Low
10/19/2017	Piper Jaffray	Set Price Target	Buy	$26.00	N/A
8/3/2017	HC Wainwright	Set Price Target	Buy	$18.00	High
4/12/2017	CIBC	Reiterated Rating	Outperform -> Outperform	$21.00	Low
11/9/2016	Aegis	Initiated Coverage	Buy	$24.00	N/A
10/10/2016	Brean Capital	Set Price Target	Buy	$24.00	N/A
8/26/2016	JMP Securities	Boost Price Target	Market Outperform	$18.00 -> $22.00	N/A

(Data available from 4/19/2016 forward)

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings History and Estimates Chart

Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($0.12)	($0.03)	($0.08)
Q2 2018	3	($0.06)	$0.02	($0.01)
Q3 2018	3	($0.57)	$0.07	($0.16)
Q4 2018	3	($0.06)	$0.12	$0.06

Vanda Pharmaceuticals (NASDAQ VNDA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		($0.17)					N/A
2/14/2018	Q4 2017	($0.12)	($0.04)	$44.00 million	$44.28 million	View	Listen
11/7/2017	Q3 2017	($0.10)	($0.10)	$43.90 million	$41.30 million	View	N/A
8/2/2017	Q2 2017	($0.21)	($0.03)	$40.31 million	$42.06 million	View	Listen
5/2/2017	Q1 2017	($0.13)	($0.17)	$38.35 million	$37.42 million	View	Listen
2/15/2017	Q416	($0.06)	($0.01)	$39.38 million	$38.24 million	View	Listen
11/2/2016	Q316	($0.14)	($0.01)	$38.05 million	$38.48 million	View	Listen
7/27/2016	Q216	($0.23)	($0.11)	$36.03 million	$36.02 million	View	Listen
5/4/2016	Q116	($0.24)	($0.17)	$32.48 million	$33.30 million	View	Listen
2/10/2016	Q415	($0.26)	($0.23)	$31.34 million	$31.85 million	View	Listen
11/3/2015	Q315	($0.20)	($0.11)	$28.58 million	$28.34 million	View	Listen
7/29/2015	Q2	($0.32)	($0.01)	$24.55 million	$27.60 million	View	Listen
5/6/2015	Q1	($0.25)	($0.24)	$20.18 million	$22.20 million	View	Listen
2/19/2015	Q4	$0.56	($0.36)	$35.57 million	$15.40 million	View	Listen
10/27/2014	Q314	($0.39)	($0.04)	$12.20 million	$14.80 million	View	Listen
8/7/2014	Q2	($0.70)	($0.64)	$10.00 million	$10.80 million	View	Listen
5/8/2014	Q1	($0.29)	($0.79)	$8.50 million	$9.10 million	View	Listen
2/13/2014	Q413	($0.20)	($0.23)	$8.50 million	$8.80 million	View	Listen
11/7/2013	Q313	($0.30)	($0.43)	$8.45 million	$8.70 million	View	Listen
7/31/2013	Q2 2013	($0.22)	($0.26)	$8.43 million	$8.30 million	View	Listen
5/9/2013	Q1 2013	($0.25)	($0.15)	$8.42 million	$8.10 million	View	Listen
2/12/2013	Q4 2012	($0.22)	($0.23)	$8.60 million	$7.90 million	View	Listen
11/7/2012	Q312	($0.22)	($0.19)	$8.40 million	$8.28 million	View	N/A
8/2/2012		($0.27)	($0.28)			View	N/A
5/8/2012		($0.16)	($0.28)			View	N/A
2/14/2012		($0.19)	($0.20)			View	N/A
11/4/2011		($0.12)	($0.11)			View	N/A
8/4/2011		($0.07)	($0.05)			View	N/A
2/10/2011		($0.02)	$0.08			View	N/A
11/3/2010	Q3 2010	$0.03	$0.11			View	N/A
8/5/2010	Q2 2010	$0.10	$0.04			View	N/A
5/4/2010	Q1 2010	$0.06	$0.02			View	N/A
2/16/2010	Q4 2009	($0.25)	($0.34)			View	N/A
11/2/2009	Q3 2009	($0.30)	($0.28)			View	N/A
8/10/2009	Q2 2009	($0.26)	($0.46)			View	N/A
4/29/2009	Q1 2009	($0.22)	($0.24)			View	N/A
2/11/2009	Q4 2008	($0.42)	($0.28)			View	N/A
10/30/2008	Q3 2008	($0.44)	($0.41)			View	N/A
8/5/2008	Q2 2008	($0.70)	($0.51)			View	N/A
5/1/2008	Q1 2008	($0.86)	($0.72)			View	N/A
2/14/2008	Q4 2007	($0.76)	($0.78)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Vanda Pharmaceuticals (NASDAQ:VNDA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 81.04%

Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2018	Gunther Birznieks	SVP	Sell	8,525	$18.72	$159,588.00	148,366
3/1/2018	James Patrick Kelly	CFO	Sell	8,532	$18.72	$159,719.04	208,066
3/1/2018	Mihael Hristos Polymeropoulos	Insider	Sell	60,966	$18.72	$1,141,283.52	1,243,838
1/2/2018	Gunther Birznieks	SVP	Sell	8,568	$15.26	$130,747.68	118,366
1/2/2018	James Patrick Kelly	CFO	Sell	9,155	$15.35	$140,529.25	144,721
1/2/2018	Mihael Hristos Polymeropoulos	Insider	Sell	191,760	$15.30	$2,933,928.00	1,031,848
1/3/2017	Richard L Gulino	SVP	Sell	10,900	$15.51	$169,059.00	12,500
9/23/2016	James E Flynn	Insider	Sell	1,120,461	$16.56	$18,554,834.16
9/19/2016	James E Flynn	Insider	Sell	547,886	$15.66	$8,579,894.76
1/4/2016	James Patrick Kelly	CFO	Sell	9,564	$8.96	$85,693.44	60,772
1/4/2016	Mihael Hristos Polymeropoulos	CEO	Sell	21,353	$8.96	$191,322.88	839,178
1/4/2016	Paolo Baroldi	SVP	Sell	12,380	$8.96	$110,924.80	40,665
12/11/2015	James E Flynn	Insider	Buy	1,201,364	$8.38	$10,067,430.32
9/10/2015	Mihael Hristos Polymeropoulos	CEO	Sell	131,739	$12.68	$1,670,450.52	816,781
5/22/2015	Mihael Hristos Polymeropoulos	CEO	Sell	186,395	$10.36	$1,931,052.20
3/9/2015	Richard W Dugan	Director	Sell	4,804	$10.69	$51,354.76
12/23/2014	James E Flynn	Insider	Buy	162,014	$14.40	$2,333,001.60
3/14/2014	Thomas Watkins	Director	Sell	35,000	$17.66	$618,100.00
11/21/2013	Robert Repella	SVP	Sell	107,500	$12.03	$1,293,225.00	15,000

(Data available from 1/1/2013 forward)

Vanda Pharmaceuticals (NASDAQ VNDA) News Headlines

Source:

Date	Headline
	Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018 finance.yahoo.com - April 19 at 9:59 AM
	Vanda Pharmaceuticals (VNDA) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 17 at 3:34 PM
	Patent on Vanda schizophrenia drug upheld by appeals court www.reuters.com - April 15 at 4:22 PM
	Vanda Pharmaceuticals (VNDA) Says It Won Case on Fanapt www.streetinsider.com - April 15 at 4:22 PM
	Vanda Pharmaceuticals Inc. (VNDA) Sees Significant Decline in Short Interest www.americanbankingnews.com - April 15 at 1:14 AM
	Vanda Pharmaceuticals (VNDA) Given a $21.00 Price Target at Oppenheimer www.americanbankingnews.com - April 13 at 8:19 PM
	Vanda Pharmaceuticals (VNDA) Given a $18.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - April 13 at 7:15 PM
	Vanda Pharmaceuticals (VNDA) PT Set at $23.00 by Piper Jaffray www.americanbankingnews.com - April 13 at 5:29 PM
	Vanda Wins Appeal Case on Fanapt® finance.yahoo.com - April 13 at 4:15 PM
	Vanda Pharmaceuticals (VNDA) Lifted to Strong-Buy at Zacks Investment Research www.americanbankingnews.com - April 12 at 7:25 PM
	Vanda Pharmaceuticals Target of Unusually High Options Trading (VNDA) www.americanbankingnews.com - April 11 at 7:04 AM
	$43.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter www.americanbankingnews.com - April 10 at 2:23 AM
	Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis finance.yahoo.com - April 9 at 4:16 PM
	Jefferies Group Analysts Cut Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA) www.americanbankingnews.com - April 9 at 2:28 AM
	-$0.09 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter www.americanbankingnews.com - April 8 at 7:10 PM
	Vanda Pharmaceuticals (VNDA) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 5 at 9:00 PM
	Vanda Pharmaceuticals (VNDA) Lowered to Sell at ValuEngine www.americanbankingnews.com - April 4 at 6:23 PM
	Oppenheimer Analysts Give Vanda Pharmaceuticals (VNDA) a $26.00 Price Target www.americanbankingnews.com - April 4 at 3:32 PM
	Vanda Pharmaceuticals (VNDA) Rating Lowered to Sell at ValuEngine www.americanbankingnews.com - March 31 at 11:34 PM
	Oppenheimer Reiterates "Buy" Rating for Vanda Pharmaceuticals (VNDA) www.americanbankingnews.com - March 30 at 1:48 PM
	Vanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 28 at 9:44 AM
	Vanda receives notice of Teva application for generic Hetlioz seekingalpha.com - March 26 at 4:19 PM
	Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $43.40 Million www.americanbankingnews.com - March 24 at 2:38 AM
	Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Post Earnings of -$0.09 Per Share www.americanbankingnews.com - March 22 at 7:10 PM
	Vanda Pharmaceuticals (VNDA) Receives "Buy" Rating from Oppenheimer www.americanbankingnews.com - March 22 at 4:09 PM
	Vanda Pharmaceuticals (VNDA) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 17 at 9:32 AM
	Pre-Open Movers 03/16: (SEED) (DXR) (VERU) Higher; (OSTK) (TIF) (W) Lower (more...) www.streetinsider.com - March 16 at 4:22 PM
	Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock finance.yahoo.com - March 16 at 10:48 AM
	Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Investors Are Paying Above The Intrinsic Value finance.yahoo.com - March 16 at 10:48 AM
	Vanda Pharmaceuticals (VNDA) Proposes Public Offering of Common Stock - StreetInsider.com www.streetinsider.com - March 14 at 4:15 PM
	Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock - PR Newswire (press release) www.prnewswire.com - March 14 at 4:15 PM
	Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock finance.yahoo.com - March 14 at 4:15 PM
	Equities Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q1 2018 Earnings (VNDA) www.americanbankingnews.com - March 8 at 6:30 AM
	Vanda Pharmaceuticals (VNDA) Reports Demonstrated Efficacy for HETLIOZ from Advanced Clinical Study - StreetInsider.com www.streetinsider.com - March 7 at 4:16 PM
	Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences - PR Newswire (press release) www.prnewswire.com - March 7 at 4:16 PM
	Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences finance.yahoo.com - March 7 at 10:33 AM
	A drug for jet lag? A D.C. drug developer says it just got a lot closer. www.bizjournals.com - March 6 at 4:13 PM
	Stonepine Capital Management LLC Has $13.45 Million Stake in Vanda Pharmaceuticals Inc. (VNDA) www.americanbankingnews.com - March 6 at 2:53 PM
	Vanda Pharmaceuticals Inc. (VNDA) Stake Boosted by University of Notre Dame DU Lac www.americanbankingnews.com - March 6 at 10:02 AM
	A drug for jet lag? A D.C. biotech says it just got a lot closer. finance.yahoo.com - March 5 at 4:25 PM
	Vanda Pharmaceuticals (VNDA) Given a $27.00 Price Target at Oppenheimer www.americanbankingnews.com - March 5 at 1:35 PM
	HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study finance.yahoo.com - March 5 at 10:51 AM
	Sei Investments Co. Grows Position in Vanda Pharmaceuticals Inc. (VNDA) www.americanbankingnews.com - March 5 at 7:36 AM
	Vanda Pharmaceuticals Inc. (VNDA) Forecasted to Earn Q1 2018 Earnings of ($0.03) Per Share www.americanbankingnews.com - March 5 at 1:10 AM
	Vanda Pharmaceuticals Inc. (VNDA) Stake Lowered by Bogle Investment Management L P DE www.americanbankingnews.com - March 4 at 4:58 AM
	Vanda Pharmaceuticals (VNDA) Lifted to "Strong-Buy" at BidaskClub www.americanbankingnews.com - March 3 at 9:30 PM
	Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - March 3 at 4:15 PM
	Insider Selling: Vanda Pharmaceuticals Inc. (VNDA) SVP Sells 8,525 Shares of Stock www.americanbankingnews.com - March 2 at 6:56 PM
	Vanda Pharmaceuticals Inc. (VNDA) CFO James Patrick Kelly Sells 8,532 Shares www.americanbankingnews.com - March 2 at 6:56 PM
	Insider Selling: Vanda Pharmaceuticals Inc. (VNDA) Insider Sells 60,966 Shares of Stock www.americanbankingnews.com - March 2 at 6:20 PM

Vanda Pharmaceuticals (NASDAQ:VNDA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Vanda Pharmaceuticals (NASDAQ:VNDA) Income Statement, Balance Sheet and Cash Flow Statement

Vanda Pharmaceuticals (NASDAQ VNDA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff